Dieckman T, Schreurs M, Lindelauf C, Mahfouz A, Meijer C, Pigeaud L
Gastro Hep Adv. 2025; 4(1):100545.
PMID: 39802487
PMC: 11719358.
DOI: 10.1016/j.gastha.2024.08.023.
Papadakos S, Chatzikalil E, Vakadaris G, Reppas L, Arvanitakis K, Koufakis T
Cancers (Basel). 2024; 16(14).
PMID: 39061246
PMC: 11275207.
DOI: 10.3390/cancers16142609.
Liang S, Zhou J, Cao C, Liu Y, Ming S, Liu X
Cell Mol Immunol. 2024; 21(7):674-688.
PMID: 38740925
PMC: 11214634.
DOI: 10.1038/s41423-024-01170-w.
Wang C, Biswas P, Islam A, Chen M, Chueh P
Cells. 2024; 13(5.
PMID: 38474377
PMC: 10930979.
DOI: 10.3390/cells13050413.
Fantini V, Ferrari R, Bordoni M, Spampinato E, Pandini C, Davin A
Cell Prolif. 2024; 57(8):e13627.
PMID: 38421110
PMC: 11294439.
DOI: 10.1111/cpr.13627.
A new target of radiotherapy combined with immunotherapy: regulatory T cells.
Song D, Ding Y
Front Immunol. 2024; 14:1330099.
PMID: 38259489
PMC: 10800811.
DOI: 10.3389/fimmu.2023.1330099.
TNF superfamily control of tissue remodeling and fibrosis.
Steele H, Cheng J, Willicut A, Dell G, Breckenridge J, Culberson E
Front Immunol. 2023; 14:1219907.
PMID: 37465675
PMC: 10351606.
DOI: 10.3389/fimmu.2023.1219907.
In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.
Abdeladhim M, Karnell J, Rieder S
Front Immunol. 2023; 13:1033705.
PMID: 36591244
PMC: 9799097.
DOI: 10.3389/fimmu.2022.1033705.
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients.
Marx S, Wilken F, Miebach L, Ispirjan M, Kinnen F, Paul S
Cancers (Basel). 2022; 14(23).
PMID: 36497232
PMC: 9739079.
DOI: 10.3390/cancers14235751.
Setd2 supports GATA3ST2 thymic-derived Treg cells and suppresses intestinal inflammation.
Ding Z, Cai T, Tang J, Sun H, Qi X, Zhang Y
Nat Commun. 2022; 13(1):7468.
PMID: 36463230
PMC: 9719510.
DOI: 10.1038/s41467-022-35250-0.
High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer.
Ke S, Xie F, Guo Y, Chen J, Wang Z, Yu Y
iScience. 2022; 25(12):105529.
PMID: 36419848
PMC: 9676631.
DOI: 10.1016/j.isci.2022.105529.
Impaired intratumoral natural killer cell function in head and neck carcinoma.
Mele D, Pessino G, Trisolini G, Luchena A, Benazzo M, Morbini P
Front Immunol. 2022; 13:997806.
PMID: 36341402
PMC: 9630640.
DOI: 10.3389/fimmu.2022.997806.
Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity.
Liu H, Wu W, Sun G, Chia T, Cao L, Liu X
Cell Rep Med. 2022; 3(6):100660.
PMID: 35732156
PMC: 9245059.
DOI: 10.1016/j.xcrm.2022.100660.
Regulation of Treg Cell Metabolism and Function in Non-Lymphoid Tissues.
Yang K
Front Immunol. 2022; 13:909705.
PMID: 35720275
PMC: 9200993.
DOI: 10.3389/fimmu.2022.909705.
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y, Tang F, Wei Y, Wei X
J Hematol Oncol. 2022; 15(1):61.
PMID: 35585567
PMC: 9118588.
DOI: 10.1186/s13045-022-01282-8.
Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer.
Vanguri R, Benhamida J, Young J, Li Y, Zivanovic O, Chi D
Gynecol Oncol Rep. 2022; 39:100926.
PMID: 35146104
PMC: 8801989.
DOI: 10.1016/j.gore.2022.100926.
Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells.
Xie Y, Xie F, Zhang L, Zhou X, Huang J, Wang F
Adv Sci (Weinh). 2021; 8(22):e2101672.
PMID: 34658167
PMC: 8596143.
DOI: 10.1002/advs.202101672.
Multiple mechanisms for TRAF3-mediated regulation of the T cell costimulatory receptor GITR.
Li H, Hostager B, Arkee T, Bishop G
J Biol Chem. 2021; 297(3):101097.
PMID: 34418432
PMC: 8441216.
DOI: 10.1016/j.jbc.2021.101097.
Lipid Metabolism and Immune Checkpoints.
Liao Q, Zhou Y, Xia L, Cao D
Adv Exp Med Biol. 2021; 1316:191-211.
PMID: 33740251
DOI: 10.1007/978-981-33-6785-2_12.
Accelerator or Brake: Immune Regulators in Malaria.
Cai C, Hu Z, Yu X
Front Cell Infect Microbiol. 2020; 10:610121.
PMID: 33363057
PMC: 7758250.
DOI: 10.3389/fcimb.2020.610121.
